Lisaftoclax with azacytidine for higher-risk myelodysplastic syndrome
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug called lisaftoclax combined with a standard treatment, azacytidine, for people newly diagnosed with higher-risk myelodysplastic syndrome (MDS). The goal is to see if the combination helps control the disease better than what's currently available.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be newly diagnosed with higher-risk myelodysplastic syndrome (MDS).
- You should be able to perform daily activities with some help (ECOG score 0-2).
- Your life expectancy should be at least 3 months.
- Your organs must be working well enough to receive the treatment.
- If you can become pregnant, you must have a negative pregnancy test and use effective birth control during treatment and for 6 months after.
- You must be able to understand and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two drugs, azacitidine and rotercept, for people with a type of blood cancer called myelodysplastic syndrome (MDS) that has a higher risk of progressing. The goal is to see if adding rotercept helps control the disease better than standard care.
This study tests a new pill (APG-2575, also called Lisaftoclax) combined with a standard injection (azacitidine) for adults with newly diagnosed AML who cannot take strong chemotherapy. The goal is to see if this combination works better than treatment alone.
This early-phase trial tests lisaftoclax, alone or with other medicines, in people whose acute leukemia has returned or did not respond to prior treatment. It aims to find out how well the treatment works and how safe it is, especially for patients who may not be able to take standard chemotherapy.
This trial tests three different chemotherapy regimens for adults 15–65 years old with newly diagnosed acute myeloid leukemia (AML)—a serious blood cancer. The goal is to see which treatment approach works best for patients with intermediate or high-risk disease who are fit enough for intensive chemotherapy.
This trial tests a drug called lisaftoclax to prevent differentiation syndrome, a serious complication that can occur during treatment of acute promyelocytic leukemia (APL). It aims to make treatment safer by reducing the risk of this side effect.
This study is testing how well a new treatment works for adults who have just been diagnosed with acute lymphoblastic leukemia (ALL), a cancer of the blood and bone marrow. It aims to see if the treatment is safe and effective in helping you reach remission.
Hear when a new Higher-risk Myelodysplastic Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.